Bernstein Rates Guardant Health (GH) buy, $175 Price Target
Bernstein has raised its rating on Guardant Health, setting a new price target, a 13.83% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Bernstein rated Guardant Health, Inc. ($GH) "buy" with a $175 price target on June 26, 2026.
Since the rating, $GH is up 13.1% after 1 week, down 2.5% after 1 month and up 6.3% to date (from the $149.22 close on Jun 26, 2026).
GH
Guardant Health, Inc.
Key Points
- Bernstein reinstated Guardant Health with a 'buy' rating and a $175 target on June 26, 2026.
- Bernstein's $175 price target implies 13.83% upside from Guardant Health, Inc.'s ($GH) current $153.74 share price.
- Guardant Health's stock traded at $142.94 on Friday, with a market cap of $18.95 billion and a 52-week high of $145.84.
- Insiders Tariq Musa and Myrtle Potter sold shares under a Rule 10b5-1 plan, while analysts from Barclays, RBC Capital, and Mizuho maintained 'buy' ratings.
Get $GH trade alerts by text
We text you when insiders, Congress or big funds trade $GH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Guardant Health, Inc. alert may contain errors. Disclosures
On June 26, 2026, Bernstein reinstated its rating on Guardant Health, Inc. (NasdaqGS: GH) with a 'buy' recommendation and set a new price target of $175. This move comes as Guardant Health's shares traded around $142.94 on Friday.
Bernstein vs. the S&P 500
Hypothetical returns from Bernstein's disclosed trades, not real profit or advice. How we model this.
Guardant Health, Inc. Stock Down 7.3%
Shares of NasdaqGS:GH traded near $142.94 on Friday. Guardant Health has a market cap of approximately $18.95 billion. The stock has experienced a 52-week low of $40.35 and a high of $145.84. Its 50-day moving average stands at $109.90, while the 200-day moving average is $95.37. The company's beta is 1.619, indicating a higher volatility compared to the market.
$GH price target
Guardant Health, Inc. daily closes and this analyst's $175 target. Not advice.
Recent Earnings
Guardant Health reported revenues of about $1.08 billion, with a growth rate of 48.3%. However, the company is not yet profitable, with a net margin of -40.1%. Its forward P/E ratio is negative at -301.1, reflecting its current unprofitability. The next earnings report is expected on July 29, 2026.
Insider Buying and Selling at Guardant Health, Inc.
Recent insider activity at Guardant Health includes sales by Tariq Musa and Myrtle Potter on June 22, 2026. Both transactions were planned under a Rule 10b5-1 plan, with Musa selling 1,951 shares and Potter selling 1,556 shares at an average price of $131.16 each. Additionally, Roberto Mignone was involved in both buying and selling activities on June 21 and May 21, 2026, though the transactions were not part of a planned trading strategy.
Analysts Set New Price Targets
On June 26, 2026, Bernstein reinstated Guardant Health with a 'buy' rating and a $175 price target. Barclays maintained its 'buy' rating with a $150 target on June 24, while RBC Capital initiated coverage with a 'buy' rating and a $185 target on June 12. Mizuho maintained its 'buy' rating with a $175 target on June 8. Overall, the consensus among 23 analysts remains strong, with a mean target price of $143.09 and a recommendation of 'strong buy'.
About Guardant Health
Guardant Health, Inc. is a precision oncology company based in Palo Alto, California. It specializes in providing blood and tissue tests for cancer detection and therapy development. The company offers various tests, including the Guardant360 CDx, a liquid biopsy for tumor mutation profiling, and the Guardant Reveal, which detects cancer at the molecular level. With a focus on advancing cancer research, Guardant Health collaborates with biopharmaceutical companies and provides integrated software solutions to connect patients with clinical studies. Founded in 2011, the company is led by CEO Dr. Helmy Eltoukhy.
Bottom Line
Guardant Health continues to garner attention from analysts and investors, with Bernstein's latest 'buy' rating highlighting its potential. The company's innovative oncology solutions position it as a key player in cancer diagnostics. Investors should note that analyst ratings and price targets are forward-looking and subject to change based on market conditions and company performance.
Related Filing Alerts
Source: Bernstein's rating change on $GH (Jun 26, 2026). Written by software, not financial advice. How we make alerts